Besides targeting Treg cells and VEGF, we also used acetylsalicylic acid to modulate tumor endothelial FasL expression and low-dose IL-2, which supports in vivo tumor-specific T cell proliferation. The gene discussed is VEGFA; the disease is neoplasm.